AU6056586A - Fusion proteins, a process for their preparation and their use - Google Patents

Fusion proteins, a process for their preparation and their use

Info

Publication number
AU6056586A
AU6056586A AU60565/86A AU6056586A AU6056586A AU 6056586 A AU6056586 A AU 6056586A AU 60565/86 A AU60565/86 A AU 60565/86A AU 6056586 A AU6056586 A AU 6056586A AU 6056586 A AU6056586 A AU 6056586A
Authority
AU
Australia
Prior art keywords
sequence
amino acids
genetically codable
genetically
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU60565/86A
Other versions
AU595221B2 (en
Inventor
Paul Habermann
Siegfried Stengelin
Friedrich Wengenmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU6056586A publication Critical patent/AU6056586A/en
Application granted granted Critical
Publication of AU595221B2 publication Critical patent/AU595221B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)

Abstract

1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A fusion protein of the general formula Met - Xn - D' - Y - Z in which n is zero or 1, X is a sequence of 1 to 12 genetically codable amino acids, D' is a sequence of about 70 amino acids in the region of the sequence of amino acids 23 - 93 of the D-peptide in the trp operon of E. coli, Y denotes a sequence of one or more genetically codable amino acids which permits the following amino acid sequence Z to be cleaved off, and Z is a sequence of genetically codable amino acids. 1. Claims for the Contracting State : AT A process for the preparation of a fusion protein of the general formula (1) Met - Xn - D' - Y - Z in which n is zero or 1, X is a sequence of 1 to 12 genetically codable amino acids, D' is a sequence of about 70 amino acids in the region of the sequence of amino acids 23 - 93 of the D-peptide in the trp operon of E. coli, Y denotes a sequence of one or more genetically codable amino acids which permits the following amino acid sequence Z to be cleaved off, and Z is a sequence of genetically codable amino acids, characterized by expressing a gene structure which codes for these fusion proteins in a host cell, and separating the fusion protein.
AU60565/86A 1985-07-27 1986-07-25 Fusion proteins, a process for their preparation and their use Expired AU595221B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853526995 DE3526995A1 (en) 1985-07-27 1985-07-27 FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE3526995 1985-07-27

Publications (2)

Publication Number Publication Date
AU6056586A true AU6056586A (en) 1987-01-29
AU595221B2 AU595221B2 (en) 1990-03-29

Family

ID=6276985

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60565/86A Expired AU595221B2 (en) 1985-07-27 1986-07-25 Fusion proteins, a process for their preparation and their use

Country Status (18)

Country Link
EP (1) EP0211299B1 (en)
JP (1) JPH07113040B2 (en)
KR (1) KR950000299B1 (en)
AT (1) ATE50596T1 (en)
AU (1) AU595221B2 (en)
CA (1) CA1336329C (en)
DE (2) DE3526995A1 (en)
DK (1) DK172618B1 (en)
ES (1) ES2000278A6 (en)
FI (1) FI86887C (en)
GR (1) GR861957B (en)
HU (1) HU197356B (en)
IE (1) IE59127B1 (en)
IL (1) IL79522A (en)
NO (1) NO175640C (en)
NZ (1) NZ216967A (en)
PT (1) PT83065B (en)
ZA (1) ZA865556B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738541A1 (en) * 1987-11-13 1989-05-24 Hoechst Ag METHOD FOR INSULATING AND CLEANING HIRUDINE
DE3541856A1 (en) * 1985-11-27 1987-06-04 Hoechst Ag EUKARYOTIC FUSION PROTEINS, THEIR PRODUCTION AND USE, AND MEANS FOR CARRYING OUT THE PROCESS
DE3781819T2 (en) * 1986-03-12 1993-01-07 Imcera Group Inc HYBRID EXPRESSION VECTORS, THEIR PRODUCTION AND USE.
WO1988010299A1 (en) * 1987-06-24 1988-12-29 Novo-Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
GR1005153B (en) * 1989-08-29 2006-03-13 The General Hospital Corporation Fusion proteins their preparation and use
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (en) * 1989-12-22 1991-06-27 Basf Ag METHOD FOR PRODUCING HIRUDINE
ES2218622T3 (en) 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh INSULIN DERIVATIVES WITH INCREASED ZINC UNION ACTIVITY.
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
PL2201120T3 (en) 2007-09-21 2014-05-30 Cadila Healthcare Ltd Gcsf fusion protein systems suitable for high expression of peptides
BR122013025625B1 (en) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL COMPOSITION, ITS USE AND METHOD OF PREPARATION OF THE SAME, KIT AND DEVICE
ES2676373T3 (en) 2009-11-13 2018-07-19 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
SI2498801T1 (en) 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
RS55378B1 (en) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
LT3229828T (en) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR68404B (en) * 1979-06-01 1981-12-29 Univ California
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
WO1986005513A1 (en) * 1985-03-18 1986-09-25 Gene Labs, Inc. Hybrid-gene cassette vector
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
ATE109512T1 (en) * 1985-04-08 1994-08-15 Genetic Systems Corp EXPRESSION AND DIAGNOSIS USING GAG-ENCODED PEPTIDES IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins

Also Published As

Publication number Publication date
HU197356B (en) 1989-03-28
AU595221B2 (en) 1990-03-29
DE3526995A1 (en) 1987-02-05
NO175640C (en) 1994-11-09
KR950000299B1 (en) 1995-01-13
ES2000278A6 (en) 1988-02-01
CA1336329C (en) 1995-07-18
KR870001312A (en) 1987-03-13
NO863000L (en) 1987-01-28
PT83065A (en) 1986-08-01
IL79522A (en) 1991-08-16
FI86887B (en) 1992-07-15
DK355486D0 (en) 1986-07-25
FI863041A (en) 1987-01-28
DK355486A (en) 1987-01-28
NZ216967A (en) 1988-08-30
HUT43629A (en) 1987-11-30
IL79522A0 (en) 1986-10-31
IE59127B1 (en) 1994-01-12
DE3669175D1 (en) 1990-04-05
EP0211299A2 (en) 1987-02-25
EP0211299A3 (en) 1988-06-01
PT83065B (en) 1989-02-28
ZA865556B (en) 1987-03-25
ATE50596T1 (en) 1990-03-15
FI86887C (en) 1992-10-26
IE861977L (en) 1987-01-27
EP0211299B1 (en) 1990-02-28
DK172618B1 (en) 1999-03-01
NO175640B (en) 1994-08-01
GR861957B (en) 1986-11-25
JPH07113040B2 (en) 1995-12-06
FI863041A0 (en) 1986-07-24
NO863000D0 (en) 1986-07-25
JPS6229600A (en) 1987-02-07

Similar Documents

Publication Publication Date Title
AU595221B2 (en) Fusion proteins, a process for their preparation and their use
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
AU561343B2 (en) Human immune interferon by recombinant dna
FI853056L (en) Process for the preparation of polypeptide with hirudin activity
DE68922917D1 (en) KEX2 endoprotease and process for its preparation.
ES8603574A1 (en) Production of polypeptides with a human gamma-interferon activity.
FI880017A0 (en) Method for preparing pancreatic trypsin inhibitor variants and DNA, vector and host cell used in the method
EP0111814A3 (en) The cloning and expression of nucleotide sequences encoding bovine growth hormone
ATE89317T1 (en) PROTEINS, EXPRESSION VECTORS CONTAINING DNA ENCODING FOR SUCH PROTEINS, AND CELLS CONTAINING SUCH EXPRESSION VECTORS.
AU9026691A (en) New human recombinant gamma interferon
EP0330700A4 (en) Human prourokinase-like polypeptide.
JPS6438099A (en) Fused protein or dihydrofolate reductase and bradykinin
IE872531L (en) Preparation of salmon calcitonin by genetic engineering, and¹means for carrying out this process
CA1267086C (en) Method of administering diuretic atrial peptides
FI934079A (en) Method for preparing a fusion protein